Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 19;17(4):234. doi: 10.3390/md17040234

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The extracellular signal-regulated kinase (ERK) and the protein kinase B (Akt) signaling pathways are affected by 3-BDB (30 µM) treatment. (a) After treatment with 3-BDB, total protein lysates were collected and analyzed for the levels of phospho-Akt, Akt, phospho-ERK1/2, and ERK1/2 with Western blotting using specific antibodies. (b) HO-1 and (c) phospho-Nrf2 levels were analyzed via Western blotting. U0126 and LY294002 are an ERK inhibitor and a PI3K inhibitor, respectively. * Significant difference compared with control (p < 0.05); ** significant difference compared with 3-BDB-treated cells (p < 0.05).

The extracellular signal-regulated kinase (ERK) and the protein kinase B (Akt) signaling pathways are affected by 3-BDB (30 µM) treatment. (a) After treatment with 3-BDB, total protein lysates were collected and analyzed for the levels of phospho-Akt, Akt, phospho-ERK1/2, and ERK1/2 with Western blotting using specific antibodies. (b) HO-1 and (c) phospho-Nrf2 levels were analyzed via Western blotting. U0126 and LY294002 are an ERK inhibitor and a PI3K inhibitor, respectively. * Significant difference compared with control (p < 0.05); ** significant difference compared with 3-BDB-treated cells (p < 0.05).